James Ballenger to Imipramine
This is a "connection" page, showing publications James Ballenger has written about Imipramine.
Connection Strength
0.423
-
Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients. J Clin Psychiatry. 1993 Jun; 54(6):224-8.
Score: 0.106
-
Effect of fluvoxamine, imipramine and placebo on catecholamine function in depressed outpatients. J Psychiatr Res. 1993 Apr-Jun; 27(2):161-72.
Score: 0.105
-
Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression. Psychopharmacol Bull. 1989; 25(1):68-70.
Score: 0.078
-
Predictors of quality of life in a long-term followup study in panic disorder patients after a clinical drug trial. Psychopharmacol Bull. 1996; 32(1):149-55.
Score: 0.032
-
Long-term follow-up after a drug trial for panic disorder. Br J Psychiatry. 1995 Oct; 167(4):487-94.
Score: 0.031
-
Three cases of panic disorder with agoraphobia in children. Am J Psychiatry. 1989 Jul; 146(7):922-4.
Score: 0.020
-
Different rates of improvement of different symptoms in combined pharmacological and behavioral treatment of agoraphobia. J Behav Ther Exp Psychiatry. 1988 Jun; 19(2):119-26.
Score: 0.019
-
CSF somatostatin in affective illness and normal volunteers. Prog Neuropsychopharmacol Biol Psychiatry. 1985; 9(4):393-400.
Score: 0.015
-
Depressed patients have decreased binding of tritiated imipramine to platelet serotonin "transporter". Arch Gen Psychiatry. 1981 Dec; 38(12):1315-7.
Score: 0.012
-
Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. Am J Psychiatry. 1987 May; 144(5):664-5.
Score: 0.004
-
Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry. 1980 Jan; 37(1):51-9.
Score: 0.003